CHMP recommends extending indication of Ruconest to children with Hereditary Angioedema.- Pharming
Related news and insights
Takeda announced that the Phase III SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of Takhzyro (lanadelumab) in patients 2 to <12 years of age in preventing hereditary angioedema (hae) attacks is complete and has met its objectives.
Takeda announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for Takhzyro (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older in Japan.
KalVista Pharmaceuticals, Inc. announced the initiation of the Phase III KONFIDENT clinical trial evaluating the efficacy and safety of KVD 900 as the first potential oral, on-demand therapy for hereditary angioedema (HAE) attacks.